An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Clinical trial NCT03029780 · COMPLETED
Trial details
- NCT number
- NCT03029780
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-16
- Primary completion
- 2017-11-27
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.